Table 2.
Baseline demographics and clinical characteristics of CM patients by reversion status after the 12-week, double-blind treatment phase.
| Patients with reversion in the DBTP (reverters)* |
Patients remaining in CM in the DBTP (non-reverters) † |
|||||
|---|---|---|---|---|---|---|
| Placebo (n = 93) |
Erenumab 70 mg (n = 96) |
Erenumab 140 mg (n = 94) |
Placebo (n = 171) | Erenumab 70 mg (n = 82) |
Erenumab 140 mg (n = 86) |
|
| Age, years | ||||||
| Mean (SD) | 41.8 (11.9) | 41.6 (10.5) | 44.2 (11.1) | 42.2 (11.2) | 41.5 (12.2) | 41.9 (10.9) |
| Min, max | 20, 66 | 18, 62 | 18, 64 | 18, 64 | 18, 64 | 19, 64 |
| Sex, n (%) | ||||||
| Female | 74 (79.6) | 84 (87.5) | 78 (83.0) | 139 (81.3) | 72 (87.8) | 77 (89.5) |
| Ethnicity, n (%) | ||||||
| White | 86 (92.5) | 87 (90.6) | 90 (95.7) | 162 (94.7) | 78 (95.1) | 84 (97.7) |
| Black or African American | 5 (5.4) | 6 (6.3) | 4 (4.3) | 4 (2.3) | 2 (2.4) | 2 (2.3) |
| Asian | 1 (1.1) | 2 (2.1) | 0 (0.0) | 3 (1.8) | 2 (2.4) | 0 |
| Other‡ | 1 (1.1) | 1 (1.0) | 0 | 2 (1.2) | 0 | 0 |
| Monthly headache days, mean (SD) | 19.0 (2.8) | 18.5 (2.7) | 19.5 (3.2) | 22.5 (3.7) | 23.1 (3.3) | 22.1 (3.8) |
| Monthly migraine days, mean (SD) | 16.2 (3.6) | 16.2 (3.3) | 16.5 (4.2) | 19.5 (4.7) | 20.1 (4.4) | 19.2 (4.9) |
| Monthly acute migraine-specific medication days, mean (SD) | 8.5 (5.9) | 8.8 (7.1) | 10.3 (6.5) | 10.0 (8.2) | 9.0 (7.4) | 9.5 (7.5) |
| Prior migraine preventive treatment failure, n (%) | 56 (60.2) | 59 (61.5) | 63 (67.0) | 129 (75.4) | 58 (70.7) | 60 (69.8) |
CM: chronic migraine; DBTP: double-blind treatment phase.
*For the DBTP, patients with reversion from CM to EM were defined as patients with < 45 headache days over the 12-week period.
†For the DBTP, patients remaining in CM were defined as patients with ≥ 45 headache days or patients with any missing monthly headache day data over the 12-week period.
‡Included American Indian or Alaska Native, Native Hawaiian or other Pacific Islander, individuals of multiple ethnic origins, and Other.